Preparation and characterization of a polyvalent human XXXX antigen vaccine.

@entity1 @entity137 @entity5 @entity56 @entity320 @entity110
A polyvalent @entity320 antigen vaccine was prepared from antigens shed by a pool of @entity1 @entity320 cells cultured in serum-free medium. The vaccine contained multiple @entity320 associated antigens (MAAs) and was free of detectable fetal calf serum (FCS) proteins and Dr antigens. Three batches of vaccine prepared several months apart contained the same spectrum of @entity5 antigens. Thirteen @entity1 with metastatic @entity320 were immunized intradermally with escalating doses of the vaccine in a Phase I study. There was no @entity137 other than transient @entity110 at the injection site. Humoral immunity, assayed by indirect immunoprecipitation, was augmented in five (38%) @entity1 . Cellular immunity, assayed by delayed-type cutaneous @entity56 , was induced in four (31%) @entity1 . Skin tests to a control vaccine prepared from pooled allogeneic lymphocytes were negative. Cutaneous metastases regressed completely in one @entity1 who is now disease free after 2 years, and multiple cutaneous metastases have remained stable for 14 months in another @entity1 . These results indicate that active immunization to a partially characterized polyvalent @entity320 antigen vaccine is safe and can increase immunity to @entity320 in some @entity1 .
